Personalis Demonstrates Ultrasensitive MRD Detection Across Multiple Cancer Types at ASCO 2026
Event summary
- Personalis presented clinical data at ASCO 2026 showing 100% sensitivity for colorectal cancer relapse detection ahead of imaging.
- NeXT Personal test detected 82% of colorectal cancer relapses just four weeks post-surgery.
- Ultrasensitive MRD detection in lung cancer showed a 3-fold increased risk of recurrence for patients with post-operative ctDNA levels below 10 ppm.
- Data across six solid tumor types demonstrated the clinical utility of ultrasensitive ctDNA detection in guiding treatment pathways.
The big picture
Personalis' ASCO 2026 data underscores the growing importance of ultrasensitive MRD detection in cancer management, positioning the company at the forefront of precision oncology. The ability to detect cancer recurrence earlier than traditional imaging methods could significantly impact treatment outcomes and guide clinical decision-making. As the field of liquid biopsies evolves, Personalis' NeXT Personal test emerges as a key player in enabling more personalized and proactive cancer care.
What we're watching
- Clinical Adoption
- The pace at which NeXT Personal gains adoption among clinicians for early cancer recurrence detection.
- Regulatory Approvals
- Whether Personalis can secure additional Medicare approvals to expand reimbursement for its tests.
- Competitive Positioning
- How Personalis differentiates its ultrasensitive MRD detection capabilities against competitors in the precision oncology space.
Related topics